ATE506372T1 - Verfahren zur herstellung von nukleosidderivate - Google Patents

Verfahren zur herstellung von nukleosidderivate

Info

Publication number
ATE506372T1
ATE506372T1 AT01966449T AT01966449T ATE506372T1 AT E506372 T1 ATE506372 T1 AT E506372T1 AT 01966449 T AT01966449 T AT 01966449T AT 01966449 T AT01966449 T AT 01966449T AT E506372 T1 ATE506372 T1 AT E506372T1
Authority
AT
Austria
Prior art keywords
nucleoside derivatives
nucleosides
producing nucleoside
derivatives
nucleoside
Prior art date
Application number
AT01966449T
Other languages
English (en)
Inventor
Leonid Beigelman
Alexander Karpeisky
Vladimir Serebryany
Peter Haeberli
David Sweedler
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Application granted granted Critical
Publication of ATE506372T1 publication Critical patent/ATE506372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
AT01966449T 2000-09-01 2001-08-31 Verfahren zur herstellung von nukleosidderivate ATE506372T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23005700P 2000-09-01 2000-09-01
US28657101P 2001-04-25 2001-04-25
PCT/US2001/027116 WO2002018405A2 (en) 2000-09-01 2001-08-31 Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives

Publications (1)

Publication Number Publication Date
ATE506372T1 true ATE506372T1 (de) 2011-05-15

Family

ID=26923871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966449T ATE506372T1 (de) 2000-09-01 2001-08-31 Verfahren zur herstellung von nukleosidderivate

Country Status (8)

Country Link
US (1) US6686463B2 (de)
EP (1) EP1313752B1 (de)
JP (1) JP2004522695A (de)
AT (1) ATE506372T1 (de)
AU (2) AU2001286959B2 (de)
CA (1) CA2421040C (de)
DE (1) DE60144479D1 (de)
WO (1) WO2002018405A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005078848A2 (en) * 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
EP2540734B1 (de) 2004-04-05 2016-03-30 Alnylam Pharmaceuticals, Inc. Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
AU2005323437B2 (en) * 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
JP2008504840A (ja) 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
AU2005328382C1 (en) 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
EP1913011B1 (de) 2004-08-04 2016-11-02 Alnylam Pharmaceuticals Inc. Oligonukleotide mit einem an einer modifizierten oder nicht-natürlichen nukleobase angebundenen liganden
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US8420613B2 (en) 2006-11-15 2013-04-16 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
US20100172882A1 (en) * 2007-01-11 2010-07-08 Glazer Peter M Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
EP2341924A4 (de) 2008-10-02 2013-01-23 David Gladstone Inst Verfahren zur behandlung von hepatitis-c-virusinfektionen
US20120149888A1 (en) * 2009-02-22 2012-06-14 Srivastava Suresh C Synthesis of ara-2'-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeuctics, diagnostics, g- tetrad forming oligonucleotides and aptamers
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411517A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2011115817A1 (en) * 2010-03-16 2011-09-22 Isis Pharmaceuticals, Inc. Methods of preparing 2'-o-substituted purine nucleosides
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
US9045521B2 (en) * 2012-07-31 2015-06-02 Ased, Llc Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides
US9512162B2 (en) 2012-07-31 2016-12-06 Ased, Llc Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides
SG11201510369WA (en) 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
CN107683336A (zh) 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
AU2017250017B2 (en) 2016-04-14 2022-12-22 Benitec IP Holdings Inc. Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
EP3516062A1 (de) 2016-09-21 2019-07-31 Alnylam Pharmaceuticals, Inc. Myostatin-irna-zusammensetzungen und verfahren zur verwendung davon
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11660311B2 (en) 2017-10-10 2023-05-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111587120A (zh) 2017-11-08 2020-08-25 艾比克斯治疗私人有限公司 免疫原性组合物及其用途
CN112105625B (zh) 2018-03-07 2024-12-31 赛诺菲 核苷酸前体、核苷酸类似物以及含其的寡聚化合物
US20220372063A1 (en) 2019-09-05 2022-11-24 Sanofi Oligonucleotides containing nucleotide analogs
IL293327B2 (en) * 2019-11-27 2026-04-01 Alnylam Pharmaceuticals Inc Synthesis of 3'-RNA oligonucleotides
US20240092819A1 (en) 2020-10-20 2024-03-21 Sanofi Novel ligands for asialoglycoprotein receptor
CN119019444B (zh) * 2023-05-24 2025-09-30 成都先导药物开发股份有限公司 一种反向脱氧核糖亚磷酰胺单体的合成方法及其中间体化合物
CN117417401B (zh) * 2023-10-19 2026-05-08 康羽生命科学技术(苏州)有限公司 一种2-tbs尿苷单体合成方法
WO2026117631A2 (en) 2024-11-26 2026-06-04 City Therapeutics, Inc. Factor xi rnai agent compositions and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
JPH0667492A (ja) 1992-08-24 1994-03-11 N T T Advance Tekunoroji Kk 像形成方法
EP1253199A1 (de) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Enzymatische Nukleinsaüre die abasische Gruppen enthalten
AU1430097A (en) * 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5962675A (en) 1996-02-13 1999-10-05 Ribozyme Pharmaceuticals, Inc. Chemical syntheses of 2'-O-methoxy purine nucleosides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP0948511B1 (de) 1996-12-24 2006-10-18 Sirna Therapeutics, Inc. Synthese von nukleosiden und polynukleotiden
JP3032815B2 (ja) 1997-02-18 2000-04-17 工業技術院長 ２’−ｏ−シリル環状ケイ素化ヌクレオシド誘導体、その製造方法及びこれを用いた２’−ｏ−シリルヌクレオシドの製造方法
EP1019497A1 (de) 1997-06-19 2000-07-19 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozyme mit erweiterte schnittregel
US6300483B1 (en) 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
CA2304813A1 (en) 1997-09-22 1999-04-08 Fritz Eckstein Nucleic acid catalysts with endonuclease activity
JP2002512794A (ja) 1998-04-29 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み

Also Published As

Publication number Publication date
JP2004522695A (ja) 2004-07-29
DE60144479D1 (de) 2011-06-01
WO2002018405A2 (en) 2002-03-07
US20020120129A1 (en) 2002-08-29
US6686463B2 (en) 2004-02-03
EP1313752A2 (de) 2003-05-28
AU2001286959B2 (en) 2007-09-06
EP1313752B1 (de) 2011-04-20
AU8695901A (en) 2002-03-13
CA2421040A1 (en) 2002-03-07
WO2002018405A3 (en) 2003-01-03
CA2421040C (en) 2010-01-12

Similar Documents

Publication Publication Date Title
DE60144479D1 (de)
ATE287413T1 (de) Verfahren zur herstellung des lna phosphoramidite
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
PT1131318E (pt) Processo para a producao de pirazoles 5-substituidos utilizando ditietanos
YU76100A (sh) Pirolo(2,3-d) pirimidin preparati i njihova primena
PT971901E (pt) Ftalazinonas
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
ATE508363T1 (de) Verfahren zur herstellung eines bioanalytischen reagenzes, nachweisverfahren beruhend auf der verwendung des bioanalytischen reagenz, sowie dessen verwendung
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
DE60103145D1 (de) Verfahren zur herstellung von phoshphorothioate triestere
ZA974952B (en) 2'-substituted nucleosides and oligonucleotide derivatives.
DE59608635D1 (de) Neues verfahren zur herstellung von nucleosiden
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
BR9917000A (pt) Processo para preparar derivados dedesaza-adenosina n6-substituìda
ATE542810T1 (de) Verfahren zur herstellung von 3,5-di-omikron-acyl-2-fluor-2-c-methyl-d-ribono gamma-lacton
ATE199724T1 (de) Verfahren zur herstellung von 1-(2'-desoxy-2',2'- difluoro-d-ribo-pentofuranosyl)-cytosin aus 2- desoxy-2,2-difluoro-beta-d-ribo-pentopyranose
DE50208851D1 (de) Gelierzucker und verfahren zu dessen herstellung
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
BRPI0408077A (pt) composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições
DE60203998D1 (de) Verfahren zur herstellung von (e)-5-(2-bromovinyl)-2'-deoxyuridin
ATE300534T1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
ATE496054T1 (de) Verfahren zur herstellung von 1,3-dioxolan- nucleosiden
ATE254627T1 (de) In situ herstellung von nukleosid- phosphoramiditen und ihre verwendung in der oligonukleotidsynthese
ATE370945T1 (de) Stereoselektives verfahren zur herstellung von nukleosidderivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties